Codexis Collaborates With Leading Biopharmaceutical Company to Apply CodeEvolver Protein Engineering in Therapeutics Development Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Codexis (CDXS) Tops Q2 EPS by 7c
August 11, 2015 4:07 PM EDTCodexis (NASDAQ: CDXS) reported Q2 EPS of ($0.07), $0.07 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $6 million versus the consensus estimate of $7.34 million.
"Solid year-to-date progress executing our plans encourages us to raise both of our annual financial guidance measures at this stage. Total revenues and gross margin in the second quarter reflected notable strength in... More
Codexis (CDXS) Enters R&D Agreement with Leading Biopharma
August 11, 2015 7:29 AM EDTCodexis (NASDAQ: CDXS) announced that it has entered into a collaborative research and development agreement with a leading global biopharmaceutical company. This is the first significant agreement in which Codexis will apply its proprietary CodeEvolver® protein engineering platform technology with a company in the biopharmaceutical industry.
Under the terms of the agreement, Codexis will employ CodeEvolver to... More
